WuXi PharmaTech FDA Approved to Manufacture API
publication date: Aug 19, 2014
A Wuxi PharmaTech subsidiary, Shanghai SynTheAll Pharma, has passed FDA inspection, allowing it to manufacture the active pharmaceutical ingredient of an unspecified commercial drug. In 2013, the same facility was granted FDA permission to produce an advanced intermediate. Drug manufacturing has become an important factor in WuXi's business -- manufacturing revenues rose 19% to $43.5 million in Q2 -- and the company's STA subsidiary provides services ranging from process research to research manufacturing to commercial manufacturing. More details....
Stock Symbol: (NYSE: WX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.